Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Guardian Therapeutics LLC is active in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. These actions are assigned to 2 distinct examiners, ensuring that each matter is under independent review. The workload is also divided between 2 distinct art units, which reflects a breadth of technical subject matter within the pharmaceutical domain. This distribution requires the applicant to monitor different examination styles simultaneously while maintaining a consistent overall strategy for the portfolio.
HUDSON, AMY ROSE is the busiest examiner for the company, who is responsible for 1 busiest examiner pending office action. The remaining pending action is assigned to the other distinct examiner. Because the portfolio is split across 2 distinct art units, the prosecution strategy may need to account for varying examination standards and timelines typical of different pharmaceutical classifications. Practitioners should be prepared to address the specific concerns of separate officials, even though the technical focus remains within the biotechnology field. The presence of multiple units indicates that the company's applications are classified under different categories, each with its own set of prior art.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PENNINGTON, KATIE LEIGH | 1 | 31.8% | +58.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17275740 | RNA POLYMERASE FOR SYNTHESIS OF MODIFIED RNA | PENNINGTON, KATIE LEIGH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17275740 | RNA POLYMERASE FOR SYNTHESIS OF MODIFIED RNA | PENNINGTON, KATIE LEIGH | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17275740 | RNA POLYMERASE FOR SYNTHESIS OF MODIFIED RNA | PENNINGTON, KATIE LEIGH | 1634 | §103§112 | Non-Final OA | — | Pending | Mar 12, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGuardian Therapeutics LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Katie Leigh Pennington has the most, with 1 of Guardian Therapeutics LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
